GBA moderates cognitive reserve's effect on cognitive function in patients with Parkinson's disease
Chia-Wen Chang1, Chun-Hsiang Tan2,3, Wei-Pin Hong4
1Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Journal of Neurology
|April 24, 2024
Summary
Cognitive reserve (CR) and Glucocerebrosidase (GBA) gene variants interact to influence cognitive function in Parkinson's disease. Understanding these genetic and life-stage factors can personalize cognitive training strategies.
Area of Science:
- Neuroscience
- Genetics
- Cognitive Aging
Background:
- Cognitive reserve (CR) aids lifelong cognitive vitality.
- Glucocerebrosidase (GBA) gene mutations affect cognition in Parkinson's disease (PD).
- The interplay between GBA mutations and CR is not well understood.
Purpose of the Study:
- To investigate the interactions among CR, GBA gene variants, and disease status.
- To determine if CR established at different life stages interacts with specific genotypes to affect cognitive function.
Main Methods:
- Evaluated CR indicators (education, occupation, social function) in 318 participants.
- Assessed comprehensive neuropsychological function including executive function, memory, and language.
- Analyzed the influence of GBA rs9628662 genotypes on cognitive performance.
Main Results:
- CR established in specific life stages impacts cognitive function, particularly in PD patients with distinct GBA rs9628662 genotypes.
- Occupational complexity in midlife affected attention/working memory and memory in PD patients (GG genotype) and healthy adults (T genotype).
- Early education and occupation influenced language, with occupational effects seen in PD patients (GG genotype) and healthy adults (T genotype).
Conclusions:
- CR, influenced by life-stage accumulation and GBA rs9628662 genotype, impacts later-life cognition.
- Genotype validation and integration into CR assessments are vital.
- This approach can enhance the effectiveness of targeted cognitive training programs.
Related Concept Videos
01:15Parkinson's Disease: Overview
537
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
537
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:30Cognitive Development During Adulthood
94
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94